<DOC>
	<DOCNO>NCT01462838</DOCNO>
	<brief_summary>Patients advance HPV- p16INK4a-positive cancer receive peptide P16_37-63 combination Montanide® ISA-51 VG immune response direct tumor cell induce . The aim show vaccination P16_37-63 safe induce enhance immune response p16INK4a .</brief_summary>
	<brief_title>Immune Therapy HPV-induced Cancers</brief_title>
	<detailed_description>The present study initiate evaluate vaccination P16_37-63 -peptide patient advance HPV- p16INK4a -positive cervical , vulvar , vaginal , penile , anal head neck cancer . Specifically , present study aim follow question : - Evaluation potential toxicity vaccination P16_37-63 -peptide - Evaluation immune response patient advance HPV- p16INK4a-positive cervical , vulvar , vaginal , penile , anal head neck cancer vaccination vaccination P16_37-63 . In context , present study shall demonstrate whether application P16_37-63 vaccination approach associate induction peptide-related toxicity . Hence , study mark first step towards application P16_37-63 human , provide information safety P16_37-63 vaccination agent first time . Moreover , study shall provide initial information , whether vaccination P16_37-63 induce p16INK4a -specific immune responses patient advance HPV- p16INK4a -positive cervical , vulvar , vaginal , penile , anal head neck cancer . Thus , shall provide information , whether P16_37-63 potential elicit peptide-specific immune response therefore represent suitable target induction tumor antigen-specific immune response population . The present study mark important milestone towards potential application P16_37-63 therapeutic agent management patient advance HPV- p16INK4a -positive cervical , vulvar , vaginal , penile , anal head neck cancer . Long-term goal approach develop novel tool palliative and/or adjuvant therapy patient advance advanced HPV- p16INK4a -positive tumor .</detailed_description>
	<criteria>Histologically confirm , advance HPVpositive cervical , vulvar , vaginal , penile , anal head neck cancer cancer progression , regression stable disease standard therapy ( still incurable ) refusal standard therapy contraindication standard treatment HPV positivity test HPV genotyping paraffin embed tumor tissue Diffuse expression p16INK4a tumor analyze immunohistochemistry paraffin embed tumor tissue . Expected survival least six month . Full recovery surgery , chemo therapy radiation therapy . ECOG performance status 0 , 1 2 . The following laboratory result : Neutrophil count ≥ 1.5 x 109/L Lymphocyte count ≥ 0.5 x 109/L Platelet count ≥ 100 x 109/L Serum bilirubin &lt; 2mg/dL Male female patient ≥ 18 year old Patient´s write informed consent participation trial Prior treatment P16_3763 peptide Clinically significant heart disease ( NYHA Class III IV ) . Other serious illness , eg , serious infection require antibiotic bleed disorder . History immunodeficiency disease autoimmune disease . Metastatic disease central nervous system therapeutic option , include radiotherapy , may available . HBV , HCV HIV positivity . Chemotherapy , type radiation therapy , immunotherapy within 4 week study entry Concomitant treatment steroid , antihistaminic drug , nonsteroidal antiinflammatory drug ( unless use low dos prevention acute cardiovascular event pain control ) . Topical inhalational steroid permit . Participation clinical trial involve another investigational agent within 4 week . Pregnancy lactation . Women childbearing potential use medically acceptable mean contraception . Psychiatric addictive disorder may compromise ability give informed consent . Lack availability patient immunological clinical followup assessment . Brain metastasis ( symptomatic nonsymptomatic )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>advanced HPV-</keyword>
	<keyword>p16INK4a-positive</keyword>
	<keyword>cervical</keyword>
	<keyword>vulvar ,</keyword>
	<keyword>vaginal</keyword>
	<keyword>penile</keyword>
	<keyword>anal</keyword>
	<keyword>head</keyword>
	<keyword>neck</keyword>
</DOC>